[144] VERACYTE, INC. SEC Filing

Rhea-AI Filing Summary

Veracyte, Inc. notice reports a proposed sale of 8,349 common shares on NASDAQ with an aggregate market value of $300,564. The shares represent restricted stock units acquired from the issuer on 12/02/2024 and were paid/issued on the same date. The filing states there were 78,671,588 shares outstanding, and the seller reports no securities sold in the prior three months. The sale is planned for 10/06/2025. The filer affirms they are not aware of undisclosed material adverse information and signs the notice consistent with Rule 144 requirements.

Positive

• Clear acquisition provenance: shares were acquired as RSUs on 12/02/2024
• No recent sales reported in the prior three months, simplifying aggregation rules

Negative

• Planned sale represents additional share supply of 8,349 shares into the market on 10/06/2025
• Filer’s material-information attestation is a single-sentence representation with no supporting detail

Insights

Securities Compliance Analyst

TL;DR: A routine Rule 144 notice for RSU-derived shares with clear timing and issuer provenance.

This filing documents a proposed sale of 8,349 common shares acquired as restricted stock units on 12/02/2024, which satisfies the acquisition provenance requirement for Rule 144 disclosure. The aggregate value is listed as $300,564, and the shares are set to trade on NASDAQ on 10/06/2025.

The primary compliance dependencies are the filer’s representation that no undisclosed material adverse information exists and the absence of related sales in the prior three months. Watch near-term trade execution around 10/06/2025 to confirm whether the planned sale occurs and if any additional Form 144s are filed.

Equity Compensation Specialist

TL;DR: Shares originate from RSUs, so vesting/issuance timing is the material factor for sale timing.

The securities were acquired as restricted stock units and recorded as issued on 12/02/2024, which is the date tied to availability for sale under Rule 144 aggregation rules. That acquisition detail explains why the filer is permitted to submit this notice for a future sale.

Key items to monitor include any subsequent disclosures about additional grants or transfers and the actual trade activity on or after 10/06/2025, which will determine how the disclosed amount impacts public float and potential market supply.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	8349	300564.00	78671588	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/02/2024	Restricted Stock Units	Issuer			8349	12/02/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Veracyte (VCYT) report in this Form 144?

The filing reports a proposed sale of 8,349 common shares with aggregate value $300,564, planned for 10/06/2025.

Where did the shares come from for the Veracyte (VCYT) sale?

The shares were acquired as restricted stock units from the issuer on 12/02/2024 and were issued/paid on that date.

How many Veracyte (VCYT) shares are outstanding according to the filing?

The filing lists 78,671,588 shares outstanding.

Were any Veracyte (VCYT) shares sold by the filer in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

On which exchange will the Veracyte (VCYT) shares be sold?

The sale is listed as planned on NASDAQ.